Details

Autor(en) / Beteiligte

• INOGUCHI, TOYOSHI
• UMEDA, FUMIO
• KAKIMOTO, MAIKO
• SAKO, YASUHIRO
• ISHII, HIDEHIRO
• NODA, KATSUMI
• KUNISAKI, MAKOTO
• IMAMURA, MINAKO
• YU, HM-YAN
• ETOH, TAKASHI
• YOSHIKAWA, HIROYASU
• AOKI, TSUYOSHI
• HASHIMOTO, TOSHIHIKO
• NAWATA, HAJIME

Titel

Chronic Sulfonylurea Treatment and Hyperglycemia Aggravate Disproportionately Elevated Plasma Proinsulin Levels in Patients with Type 2 Diabetes

Ist Teil von

• Endocrine Journal, 2000, Vol.47(6), pp.763-770

Ort / Verlag

Japan: The Japan Endocrine Society

Erscheinungsjahr

2000

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• It is established that disproportionately elevated plasma proinsulin levels occur in patients with Type 2 diabetes. In the present study, multivariate analysis was performed to determine what factors contributed to the disproportionately elevated plasma proinsulin levels in Japanese patients with Type 2 diabetes (n=276). Results from univariate analysis showed that both fasting proinsulin/C-peptide ratio and proinsulin/IRI ratio were approximately 2-fold higher in patients with Type 2 diabetes than those in healthy nondiabetic subjects (n=45). In patients with Type 2 diabetes, both proinsulin/C-peptide ratio and proinsulin/IRI ratio were significantly positively correlated with fasting plasma glucose level (FPG) and HbA1c. Neither proinsulin/C-peptide ratio nor proinsulin/IRI ratio was significantly correlated with BMI. Sulfonylurea-treated subjects had a significant elevation in both proinsulin/C-peptide ratio and proinsulin/IRI ratio compared with diet-treated subjects, whereas nonsulfonylurea hypoglycemic agent-treated subjects did not. Multivariate analysis confirmed that sulfonylurea treatment and FPG were significant determinants of both fasting proinsulin/C-peptide ratio (P=0.006 and P=0.030, respectively) and proinsulin/IRI ratio (P=0.003 and P=0.016, respectively) in patients with Type 2 diabetes. These results imply that disproportionate hyperproinsulinemia may reflect an excessive overwork of β cells under chronic sulfonylurea treatment as well as hyperglycemia.